FDA-Approved Infusion Therapies for Alzheimer's Disease
The "dementia infusion treatment" refers to FDA-approved anti-amyloid monoclonal antibodies administered intravenously for early-stage Alzheimer's disease: lecanemab (Leqembi) and donanemab (Kisunla) are the currently available disease-modifying infusion therapies, while aducanumab (Aduhelm) has been discontinued. 1
Currently Available Infusion Therapies
Lecanemab (Leqembi)
- FDA Status: Full traditional approval (July 2023) with CMS reimbursement when patients are registered in approved registries 1
- Administration: Intravenous infusion every 2 weeks 2
- Indication: Early-stage Alzheimer's disease (mild cognitive impairment or mild dementia) with confirmed brain amyloid pathology 3
- Mechanism: Targets and removes amyloid-beta plaques from the brain 4
- Clinical Benefit: 27% reduction in clinical worsening on CDR-SB scale (mean difference -0.45) over 18 months, representing modest but statistically significant slowing of cognitive decline 5
Donanemab (Kisunla)
- FDA Status: Traditional approval recommended unanimously by FDA advisory panel (June 2024) 1
- Administration: Intravenous infusion once every 4 weeks 2
- Indication: Early symptomatic Alzheimer's disease with confirmed amyloid pathology 6
- Mechanism: Targets pyroglutamate-modified amyloid-beta aggregates 6
Aducanumab (Aduhelm) - Discontinued
- FDA Status: Accelerated approval granted (June 2021), but development and sale discontinued 1
- Historical Note: CMS did not support payment, severely limiting its use before discontinuation 1
Critical Safety Considerations
Amyloid-Related Imaging Abnormalities (ARIA)
Both lecanemab and donanemab carry significant risk of ARIA, which includes:
- ARIA-E (edema): Vasogenic brain edema
- ARIA-H (hemorrhage): Cerebral microhemorrhages and rare macrohemorrhages 7
- Incidence: Approximately 21.5% with lecanemab versus 9% with placebo 5
- Risk Factors: APOE4 gene carriers, especially homozygotes, face substantially higher ARIA risk 3
Absolute Contraindications
Patients requiring anticoagulation should NOT receive these therapies until more safety data are available, as anticoagulation significantly increases hemorrhage risk 3
Required Pre-Treatment Workup
Before initiating infusion therapy, patients must have:
Confirmed amyloid pathology via:
APOE genotyping to assess ARIA risk and inform patient discussions 3, 8
Baseline brain MRI to monitor for ARIA during treatment 1
Cognitive staging confirming mild cognitive impairment or mild dementia (not moderate-to-severe dementia) 3
Monitoring Requirements
- Serial MRI scans throughout treatment to detect ARIA 7
- Clinical assessment for infusion reactions and neurological symptoms
- Institutional preparedness with protocols for managing serious adverse events 3
Comparison to Traditional Dementia Medications
These infusion therapies differ fundamentally from oral medications:
Traditional oral medications (donepezil, rivastigmine, galantamine, memantine):
- Provide only symptomatic relief 4
- Do NOT modify disease progression 4
- Administered orally, typically daily 9, 10
Infusion therapies (lecanemab, donanemab):
- Target underlying disease pathology (amyloid plaques) 4
- Provide disease-modifying effects with modest slowing of decline 5
- Require IV administration every 2-4 weeks 7, 2
- Carry significant monitoring burden and ARIA risks 7, 3
Patient Selection Algorithm
Appropriate candidates:
- Early-stage AD (MCI or mild dementia only)
- Confirmed amyloid pathology
- No anticoagulation requirement
- Able to undergo regular MRI monitoring
- Understanding of modest benefits versus significant risks
- Access to specialized infusion centers with multidisciplinary teams 1
Inappropriate candidates:
- Moderate-to-severe dementia 3
- Cognitively unimpaired individuals 1
- Patients requiring anticoagulation 3
- Inability to comply with monitoring requirements
- Dementia suspected due to Lewy body disease 1
Clinical Reality
The clinical benefit of these infusion therapies is modest - the observed improvement falls short of what is typically considered the minimal clinically significant difference for this population 5. However, they represent the first treatments that actually modify disease progression rather than merely treating symptoms 4. The decision to use these therapies requires careful weighing of modest cognitive benefits against substantial monitoring burden, infusion requirements, ARIA risks, and costs 8.